Tarnagulla Ventures
Venture capitalMelbourne · Pre-Seed–Series A · 2 people tracked
Find your way into Tarnagulla Ventures
4,157 people in our graph share verified history with the Tarnagulla Ventures team — schools, employers, funds. One of them is your warm intro.
.jpg)
Investment thesis
Tarnagulla Ventures is an exclusively life science and healthcare investor, providing seed and early-stage venture capital to promising companies. It follows a concentrated, low-frequency investment approach, favoring fewer but deeper commitments so it can dedicate significant time to nurturing portfolio companies with strategic support. Beyond financial capital, the firm emphasizes contributing intellectual capital drawn from its experience in small molecule, protein, and cell-based therapeutics. As value investors, it treats the initial investment as the beginning of a long-term partnership. Although headquartered in Melbourne, Australia, most of its investments are in US-based companies, and it focuses on bringing medical technology to Australian and US markets.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website
What they invest in
from 5 of 8 portfolio companiesBiotech ×4Healthtech ×4Medical Devices ×2Digital Health ×1
HQs:United States×4
Investments · 8 tracked
founders shown can be your intro pathClinical-stage specialty pharmaceutical company developing therapies for rare single-gene-deficiency diseases, including its JOTROL formulation of Resveratrol.
HealthtechJupiter, US
Jacob Uittenbogaard(Chief Financial Officer, Treasurer and Secretary)inMarshall Hayward(Chief Scientific Officer)Christer Rosen(Chief Executive Officer and President)inAlison Silva(Chief Operating Officer)Saleem Elmasri(Chief Financial Officer)Alexander Rosen(Chief Administrative Officer)in
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
BoardEdmund Sullivan(Director)Vincent Grattan(Director)
Co-investorsPontifax Venture CapitalVida VenturesTCG Crossover
Clinical-stage biopharmaceutical company developing best-in-class aryl hydrocarbon receptor agonists.
BiotechEncino, US
Matthew Davidson(Executive Officer, Director)
BoardDennis Brown(Director)
Co-investors7G BioVentures
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsAmorChemGenesys CapitalJDRF T1D FundNew Enterprise Associates (NEA)
Lubricin (PRG4) is a glycoprotein found naturally in the human body that lubricates and protects tissue surfaces from friction and wear.
BiotechHealthtechMedical Devices
Co-investorsThynk Capital
Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.
BiotechDigital HealthHealthtechMedical DevicesFort Worth, US
Michael Wall(Executive Officer)inDavid Wohlberg(Executive Officer, Director)Jami Kern(Executive Officer)inHalden Conner(Executive Officer, Director)inCharles Lieser(Executive Officer)Carol Lakkis(Director/R&D Technical Director)in
Develops science-based probiotic biotherapeutics to support maternal microbiome health during pregnancy and reduce infant food allergy risk.
Exits · 4
IPOs and acquisitions across the tracked portfolioJupiter Neurosciences, Inc.NASDAQ: JUNSJupiter Orphan TherapeuticsNASDAQ: JUNSLB PharmaceuticalsNASDAQ: LBRXInversagoacq. by Novo Nordisk
Portfolio news
latest coverage across their companiesAzora Therapeutics · stocktitan.net · Aug 11, 2026
Nacuity Pharmaceuticals · nasdaqprivatemarket.com · Apr 3, 2026
Frequently asked questions
- How many investments has Tarnagulla Ventures made?
- Tarnagulla Ventures has 7 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Tarnagulla Ventures invest at?
- Tarnagulla Ventures invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Tarnagulla Ventures focus on?
- Tarnagulla Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Tarnagulla Ventures located?
- Tarnagulla Ventures is headquartered in Melbourne, AU.
- Who does Tarnagulla Ventures co-invest with?
- Tarnagulla Ventures most often shares deals with Genesys Capital, JDRF T1D Fund, New Enterprise Associates (NEA), among 8 tracked co-investors.
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.